Committed to reducing lung cancer morbidity around the world, Medtronic`s (MDT) Minimally Invasive Therapies Group recently launched a 2,500-patient, international study to assess real-world impact of its superDimension(TM) navigation system. The Company developed the study to support and validate the superDimension system, which the Company hopes will become the global standard-of-care for obtaining lung tissue biopsies from the periphery of the lungs.
The LungGPS(TM) technology used in the superDimension system is the first of its kind to enable Electromagnetic Navigation Bronchoscopy procedures (also known as ENB procedures). ENB procedures provide a minimally invasive approach to access difficult-to-reach areas of the lung, which can aid in the diagnosis of lung disease and thereby lead to earlier, personalized treatment – potentially saving lives.
With a historical lack of effective, non-invasive diagnostic technologies, lung cancer remains the number one cancer killer in the world, accounting for more cancer deaths than breast, colon and prostate cancer combined.
Medtronic plc (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in about 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.